利索-全球专利检索

  1. 登录
  2. 注册
发明公开
CN106727460A Atropurpuran的衍生物组合物用于抗肝纤维化 无效 - 撤回

Atropurpuran的衍生物组合物用于抗肝纤维化
摘要：
本发明涉及有机合成和药物化学领域。本发明公开了Atropurpuran的衍生物组合物用于抗肝纤维化，即由Atropurpuran的O‑(二乙氨基)乙基衍生物(III)和O‑(二(2‑甲硫基乙基)胺基)乙基衍生物(IV)按照质量比为75：25组成的组合物以及将上述化合物按照75：25的质量比进行混合从而制备本发明组合物的方法。药理学实验表明，本发明提供的这种组合物在20ug/ml时能够显著抑制NIH/3T3增殖以及转化生长因子‑β1诱导的成纤维细胞增殖，具有抗肝纤维化作用，因此本发明还提供了Atropurpuran的衍生物(IV)按照质量比75：25组成的组合物在制备抗肝纤维化药物中的用途，
摘要（英）：

The invention relates to the field of organic synthesis and pharmaceutical chemistry and discloses application of a derivative composition of Atropurpuran to resistance of liver fibrosis, namely a composition composed of an O-(diethylamino) ethyl derivative (III) and an O-(di(2-methylmercaptoethyl)amino) ethyl derivative (IV) of the Atropurpuran at the mass ratio of 75 to 25 and a method for preparing the composition by mixing the compounds at the mass ratio of 75 to 25. A pharmacology experiment shows that the composition provided by the invention can be used for remarkably inhibiting NIH/3T3 proliferation and transforming growth factor-beta1 induced fibroblast proliferation when the concentration is 20mug/ml; the composition has the liver fibrosis resisting effect, so that the invention also provides application of the composition composed of the derivative (III) and the derivative (IV) of the Atropurpuran at the mass ratio of 75 to 25 to preparation of a medicine for resisting the liver fibrosis. (The formula (III) is shown in the description and the formula (IV) is shown in the description.).

0/0